SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

Search

Fagron

Gesloten

SectorGezondheidszorg

19.26 0.52

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.86

Max

19.3

Belangrijke statistieken

By Trading Economics

Inkomsten

-298K

40M

Verkoop

13M

443M

K/W

Sectorgemiddelde

17.346

63.778

Dividendrendement

1.58

Winstmarge

9.066

Werknemers

3,828

EBITDA

-4.3M

71M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+20.59% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.58%

2.39%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

19M

1.4B

Vorige openingsprijs

18.74

Vorige sluitingsprijs

19.26

Fagron Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 apr 2025, 23:04 UTC

Top Nieuws

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 apr 2025, 22:40 UTC

Belangrijke Marktbewegers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 apr 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 apr 2025, 18:51 UTC

Acquisities, Fusies, Overnames

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 apr 2025, 23:43 UTC

Marktinformatie

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 apr 2025, 23:41 UTC

Marktinformatie

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 apr 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 22:21 UTC

Acquisities, Fusies, Overnames

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 21:43 UTC

Top Nieuws
Winsten

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 apr 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

3 apr 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 apr 2025, 20:43 UTC

Marktinformatie

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 apr 2025, 20:34 UTC

Top Nieuws

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 apr 2025, 20:23 UTC

Top Nieuws

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 20:15 UTC

Acquisities, Fusies, Overnames

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 apr 2025, 19:55 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2025, 19:55 UTC

Marktinformatie

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 apr 2025, 19:21 UTC

Marktinformatie

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 apr 2025, 19:15 UTC

Marktinformatie

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 apr 2025, 18:45 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:45 UTC

Marktinformatie

Gold Drops In Tariff Fallout -- Market Talk

3 apr 2025, 18:39 UTC

Marktinformatie

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 apr 2025, 18:38 UTC

Top Nieuws

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 18:30 UTC

Top Nieuws

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 apr 2025, 18:20 UTC

Marktinformatie

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 apr 2025, 18:18 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:17 UTC

Marktinformatie

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 apr 2025, 18:04 UTC

Marktinformatie

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 apr 2025, 17:55 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Fagron Prognose

Koersdoel

By TipRanks

20.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19.5 EUR  20.59%

Hoogste 19.5 EUR

Laagste 19.5 EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fagron - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.